EU/3/20/2320

About

On 21 August 2020, orphan designation EU/3/20/2320 was granted by the European Commission to CambPharma Solutions (CY) Limited, Cyprus, for copper histidinate (also known as CUTX-101) for the treatment of Menkes disease.

Key facts

Active substance
Copper histidinate
Disease / condition
Treatment of Menkes disease
Date of first decision
21/08/2020
Outcome
Positive
EU designation number
EU/3/20/2320

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

CambPharma Solutions (CY) Limited
D. Vrachimis Building
Agiou Athanasiou 59
Agios Athanasios, Limassol 4102
Cyrpus
Tel. +441480465755
E-mail: pallavshah@cambreg.co.uk

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating